Novartis loses initial bid to block generic of best-selling heart drug
Novartis failed to convince a Delaware federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to a court decision issued on Monday.
US FDA approves Novartis' kidney disease drug
The U.S. Food and Drug Administration has approved the use of Novartis' drug to treat patients with a type of kidney disease, the health regulator's website showed on Wednesday.
Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims
Novartis and Viatris were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development.
Novartis: Another Beat, Another Raise
The company continues to deliver strong turnover growth and core margin expansion. Ongoing buyback combined with a juicy dividend yield provides downside protection. Positive contributions from newer drug launches. Novartis raised the 2024 core operating income guidance. Our buy rating is then confirmed.
Why Novartis Deserves Your Attention After Q2 2024 Results
On July 18, Novartis AG released its second-quarter 2024 financial results, which were solid. The company's free cash flow was about $4.62 billion for the second quarter of 2024, up 40% year over year, primarily due to strong sales of its oncology franchise. So, Kisqali sales amounted to $717 million for the three months ended June 30, 2024, an increase of 45.4% year-on-year.
Pharma Leader Beats on Earnings, But Shares Fall
Novartis NYSE: NVS is the seventh largest pharmaceutical company in the world, and is based in Switzerland. The firm reported Q2 2024 financial results on Jul. 18, 2024.
Why Novartis Stock Is Down Today Despite Topping Q2 Estimates
Drugmaker Novartis' second-quarter results were better than expected. Profit guidance for the remainder of the year was also raised.
Novartis Falls Despite Earnings Beat, Guidance Raise
Novartis (NVS) American depositary receipts (ADRs) slipped Thursday even though the pharmaceutical giant beat second-quarter earnings expectations and raised its full-year core operating income guidance.
Novartis (NVS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Novartis (NVS) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Novartis (NVS) Tops on Q2 Earnings, Ups Operating Income View
Novartis' (NVS) second-quarter earnings and sales beat estimates. Based on strong momentum, the company raises its operating income outlook for 2024.
Novartis raises 2024 profit guidance for second time
Swiss drugmaker Novartis raised its 2024 earnings guidance for the second time on Thursday, driven by a gain in prescriptions of drugs including heart failure treatment Entresto and Kesimpta for multiple sclerosis.
Here's Why Novartis (NVS) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
